Favorable Safety Outcomes Observed in Ozanimod (#Zeposia) Over Diroximel Fumarate (Vumerity)
Feb 26, 2023 – Marco Meglio – #ACTRIMS Conferences: Americas Committee for Treatment and Research in Multiple Sclerosis…
BTK Inhibitor Evobrutinib Displays Superior Efficacy Compared With Anti-CD20 Treatment for MS
Feb 25, 2023 – Isabella Ciccone, MPH A preclinical assessment of evobrutinib showed it demonstrated superior efficacy in targeting compartmentalized…
Stuart Schlossman
Zeposia’s long-term use doesn’t affect heart health, Phase 3 trials show
by Andrea Lobo, PhD | February 14, 2023 No major heart rate or echocardiogram changes over year or more of…
Stuart Schlossman
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis The Antelope Phase 3 Randomized Clinical Trial
Bernhard Hemmer, MD1; Heinz Wiendl, MD2; Karsten Roth, PhD3; et al Hendrik Wessels, PhD3; Josef Höfler, PhD4; Cyrill Hornuss, MD5; Bernd Liedert, PhD5; Krzysztof Selmaj, MD, PhD6 Author Affiliations Article Information JAMA Neurol. Published online January 23, 2023. doi:10.1001/jamaneurol.2022.5007 Key Points Question Does proposed biosimilar…
Stuart Schlossman
• Learning about Visual Disturbances in MS
Event date: August 27th / Published Date: September 21, 2022 Listen with Dr. Jonathan Calkwood’s In-Depth discussion on Topics: •…
Stuart Schlossman
FDA OKs Phase 3 Trial of Masitinib for Progressive Forms of MS
By Lindsey Shapiro, PhD on 01/03/2023 The U.S. Food and Drug Administration (FDA) has cleared AB Science to initiate a Phase 3…
Stuart Schlossman
Ocrevus Reduces Disease Activity, Slows Progression in RRMS, PPMS
Therapy works by killing off antibody-producing B-cells involved in inflammatory responses by Joana Vindeirinho, PhD | December 21, 2022 Ocrevus…
Stuart Schlossman
BREAKING NEWS::: TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy) for Multiple Sclerosis
December 28, 2022 BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple…
Stuart Schlossman
Under the microscope: what is the potential of BTK inhibitors (BTKI) ?
information provided by: MS Society UK Bruton’s tyrosine kinase (BTK) inhibitors are an emerging type of disease modifying therapy (DMT)…
Stuart Schlossman
FDA requests additional information, extends goal date for application of MS treatment
November 18, 2022 The FDA has extended the Prescription Drug User Fee Act goal date to Dec. 28, for TG…
Stuart Schlossman
